Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
(Reuters) - Pfizer Inc on Friday cut forecast for 2023 revenue to between $58 billion and $61 billion, from $67 billion to $70 billion previously.
Shares of the company were down about 7% in extended trading.
The company also reduced its outlook for Paxlovid revenues by about $7 billion. It had previously expected Paxlovid revenues of about $8 billion.
Pfizer added the U.S. government will be returning an estimated 7.9 million doses of Paxlovid at the end of this year. (This story has been corrected to say that the revenue outlook for Paxlovid was reduced by $7 billion, not to $7 billion, in paragraph 3)
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
